Start offering CellTolerance® to your patients today.

Up to 12% of the US population is reported to have IBS1. Only half of patients with IBS receive a definitive diagnosis after seeing a physician. With CellTolerance® you can offer a complete program towards a healthier life by addressing food intolerances.

Address a large patient cohort

Up to 12% of the US population is reported to have IBS1. According to our YouGov survey, many struggle for years without finding a definite resolution.

Offer a comprehensive program to relieve patients

At the heart of this program is the revolutionary CellTolerance Test, which helps you identify and manage specific intolerances.

Achieve proven results through multiple clinical studies

96% of patients improved their symptoms with cell-response guided diet2 and patients reported better improvement than with Low-FODMAP Diet3.

Open a new service line and differentiate your clinic.

Stand out by providing unique, evidence-based care that addresses a significant unmet patient need.

Contact us

Get in touch with the CellTolerance® team.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

References

  • CheyWD, KurlanderJ, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015 Mar3;313(9):949-58. doi:10.1001/jama.2015.0954
  • Fritscher-RavensA, PflaumT, Mösingeret al. Many Patients With Irritable Bowel Syndrome Have Atypical Food AllergiesNot Associated With Immunoglobulin E. Gastroenterology. 2019Jul;157(1):109-118.
  • Fritscher-RavensA, Exclusion of atypical food allergens detected by confocal endomicroscopy issuperior to low fodmap diet in patients with food-sensitive IBS. AGAABSTRACTS|VOLUME158,ISSUE6,SUPPLEMENT1,S-135, MAY 01, 2020